Carrier estimations in Duchenne muscular dystrophy families in Northern Ireland using RFLP analysis

E D Kelly, C A Graham, A J M Hill, N C Nevin

Abstract
Intragenic RFLP analysis was used to provide carrier risk estimations on 100 possible female carriers from 22 Duchenne muscular dystrophy families. This enabled 78% of possible carriers to be assigned high or low risks (>90% or <10%) as opposed to 26% assigned low risk on pedigree data alone. When a single polymorphism is not informative the use of haplotype analysis for carrier estimations is illustrated for one family.

Duchenne muscular dystrophy (DMD) is one of the most common X linked recessive disorders with an incidence of 1 in 3500 male births. It has a high mutation rate and approximately one third of cases are the result of de novo mutations.1 The DMD gene has been localised to the Xp21.2 region by a variety of cytogenetic and molecular techniques.2 A series of intragenic probes which show several high frequency, site type, restriction fragment length polymorphisms (RFLPs) can be used for gene tracking and thus carrier estimation and prenatal diagnosis in DMD families.3 4

Recently the entire coding sequence of the DMD gene has been cloned and around 70 exons are spread over approximately 2 megabases of DNA. Analysis of DMD males with cDNA probes has shown that 60 to 70% have mutations causing exon deletion.5

Linkage studies with the intragenic pERT and XJ probes have shown an average recombination rate of around 5%,6 7 probably owing to the large size of the gene and the heterogeneity of the mutation site. In this study a combination of seven polymorphisms have been used for gene tracking in 22 DMD families and revised risks have been computed for 100 females who are possible carriers of the DMD gene.

Materials and methods
SAMPLE COLLECTION AND DNA EXTRACTION
Venous blood (20 ml) was collected into 50 ml centrifuge tubes containing 5 ml of 5% EDTA, pH 8.0, as anticoagulant. The red cells were lysed and the white cell pellet collected by centrifugation. This could be stored for up to one month at -20°C before processing. DNA extraction was carried out by a method based on that of Jeanpierre.7

DNA PROBES
Four intragenic DNA probes were used to detect seven different polymorphisms (fig 1). A recombination rate of 5% was used in all risk calculations based on these probes.

DNA ANALYSIS
DNA (5 to 10 μg) from the appropriate family members was digested with restriction enzymes according to the manufacturers' instructions. The resulting fragments were size fractionated by electrophoresis in 0.8% agarose gels (Bethesda Research Laboratories). The fragments were transferred to nylon membranes (Hybond-N, Amersham) by the method of Southern8 or by vacuum blotting using the Hybaid Vacuaid system. The DNA was covalently bound to the membrane by UV photocrosslinking (305 nm for 90 seconds). The probe insert was electrophoretically purified and 50 ng was labelled with a 32P-dCTP using the random hexanucleotide primer method of Feinburg and Vogelstein9 (Multiprime Kit, Amersham). Unincorporated nucleotides were removed by gel filtration on a Sephadex G–50 column and the specific activity of the probe was measured by scintillation counting (usually 5 to 10×106 dpm/μg DNA). The membrane was incubated for a minimum of four hours at 42°C in a formamide based prehybridisation buffer (50% formamide, 0.1% Denhardt's, 1% SDS, 5×SSPE, 5% dextran sulphate, and 400 μg/ml sheared salmon sperm DNA). The hybridisation solution was the same without salmon sperm DNA, which was added to the labelled probe before denaturation. The membrane was hybridised at 42°C overnight and then washed in 2×SSPE at room temperature followed by 65°C washes at in-
creasing stringency as required. The membranes were then placed in x ray cassettes with intensifying screens and Fuji RX medical x ray film and exposed at -70°C for one to four days before development.

**Results and discussion**

RFLP analysis has been carried out on a total of 22 DMD families in Northern Ireland. Twelve of the families had isolated cases of DMD and the carrier status of the mother was unknown. In a further two families the mother was judged to be a carrier since she had more than one affected son. The remaining families showed a definite familial mode of inheritance.

Definite carriers and mothers of affected males were screened for heterozygosity with a series of six RFLPs using the intragenic pERT87 and XJ probes; examples of each polymorphism are shown in fig 1. The MspI/87–1 polymorphism was used to provide information in only one family but was not included in routine screening. Thirty four out of 39 females (87%) tested have proved informative with at least one probe. XmnI and TaqI digests were run initially since these enzymes detect five of the six RFLPs. The XmnI/87–1 and TaqI/87–15 XJ polymorphisms have proved the most informative and simple to use.

Complete RFLP analysis has been carried out on 22 families using a combination of the markers described above. Generally, once informativeness was established for a family carrier estimations were calculated on the basis of RFLP data from one, or at the most two, probes. The final risk estimation on a female was calculated from a combination of pedigree and RFLP information using the MLINK computer program. CK values from females have not been included in the overall risk estimation since a standard range of values for obligate carriers had not been established; a high CK value is, however, considered when counselling females at risk. This is particularly important in simplex families where RFLP analysis may give little information. In familial cases of DMD the majority of female relatives can be assigned 5% or 95% carrier risks based on RFLP analysis. High carrier risks can only be obtained when the disease is familial, and accurate prenatal diagnosis can be offered to such females.

The accuracy with which analysis can be carried out in isolated cases is much more variable. When the carrier status of a mother with an affected boy is unknown it is not possible to raise the risk of any of her daughters above the mother’s risk, though their risks could be reduced if they had inherited the alternative maternal allele to the affected boy. In three

---

**Figure 1** Autoradiographs of 32P–dCTP labelled probes hybridised to restriction digested total human DNA. Seven polymorphisms of the pERT and XJ intragenic DMD probes are shown with allele sizes in kilobases.
of the sporadic families the risk to the second degree female relatives was reduced to a negligible value since the disease associated allele was inherited from the grandfather of the affected male. However, the mother’s risk and that of any daughters could not be altered in this way. Six female sibs of affected males from four families were virtually excluded as carriers on the basis of not having inherited the disease associated allele from their mother. In a further four families the risks to possible carriers was significantly reduced since it was shown that both affected and normal males in the same family shared a common allele. In isolated cases this is more likely to be the result of a new mutation in the affected male than recombination.

Risks based on RFLP analysis have now been obtained on 100 females from the 22 families analysed. Each subject’s risk before and after RFLP analysis was calculated using the MLINK computer program. The results are summarised in fig 2. Before RFLP analysis only 26% of females had a carrier risk of 10% or less, with the remainder showing an even spread in risks up to 60%. However, on the basis of RFLP analysis 67% of females have risks of 10% or less. A further 11% of the females now have a high risk of greater than 90% and are solely from families where DMD shows familial inheritance. The risks for the remaining 23% of females are fairly evenly spread. In 78% of the females the risks were altered through direct RFLP results. However, for the remaining 22% RFLP data were either not available because no DNA was obtained or proved unnecessary. The risks for these females were altered on the basis of RFLP data available for close relatives.

Many DMD families prove unsuitable for RFLP analysis with a single polymorphism because the DNA from important family members is not available. We provide an example of such a DMD family in which the proband was concerned about her carrier status and was pregnant at the time. The only living affected male was a cousin whose mother was dead, as were the maternal grandparents, making routine RFLP analysis impossible. Deletion screening of the affected male proved negative and therefore we attempted a carrier estimation on the proband on the basis of haplotype analysis. RFLP data was obtained on four polymorphisms as shown in fig 3. The affected male (III.3) and his normal uncle (II.1) both share the same haplotype, indicating that the grandmother (I.1) was homozygous for all the alleles. The haplotype of her daughter (II.2), a definite carrier, allowed the haplotype of the grandfather (I.2) to be inferred. The proband (III.2) has inherited the normal maternal chromosome, as has her half sister (III.1). The two polymorphisms of the pERT87-15 probe were sufficient to define an informative haplotype and were used for risk calculation using MLINK. Their carrier risks have therefore been reduced from 50% to 8.8% and the proband now has a 1 in 45 chance of having an affected boy. The use of haplotypes can have an important, if limited, application in such families but is no more accurate for use on a routine basis.

**Conclusion**

We have provided carrier estimations on 100 females from 22 DMD families using RFLP analysis. Key females were screened for heterozygosity with the probes previously described and this strategy has

---

**Figure 2**  Diagram illustrating the effectiveness of RFLP analysis in providing carrier risk estimations in DMD. All risks were calculated using MLINK from LINKAGE v3.5 and risks before RFLP analysis were based on pedigree data only.
Figure 3 Pedigree illustrating the use of haplotype analysis for carrier estimations. The haplotypes of the affected boy III.3 and his normal uncle II.2 are the same, implying that the grandmother I.1 was homozygous for all probes. However, from the haplotypes of obligate carrier II.2 the grandfather's haplotype could be inferred, and both at risk females III.1 and III.2 were shown to have inherited the grandpaternal haplotype from their mother, thus reducing their carrier risks from 50% to 8.8% (MLINK). A: pERT87.1/XmnI, B: pERT87.15/XmnI, C: pERT87.15/Tagl, D: XJ1.1/Tagl.

proved both effective and efficient for future analysis of the families. Markers flanking the DMD gene were not used in this study because of the difficulty in obtaining two informative bridging probes. However, this strategy can improve the accuracy of risk estimations, that is, informative bridging probes showing 10% recombination each can give 99% risk estimates.

Our results reflect the advantages and limitations of the use of intragenic RFLP analysis for providing carrier estimations on females at risk. Such analysis is both useful and accurate where the disease is obviously familial. Risks can be calculated with a maximum of 95% certainty and high risk females then have the option of an accurate prenatal test.

However, only eight of our families show classical familial inheritance with most of the remainder being isolated cases. The usefulness of RFLP analysis in such families is much more variable. We were able to reduce the risks of 56% (20/36) of females, with prior risks of 10 to 60%, to below 6%, thus removing the need for non-deletion based prenatal tests in these females.

Overall there has been a polarisation of risks at the two extremes after RFLP analysis with 78% of females now within either high or low risk categories. However, for approximately 20% of females RFLP analysis has been of little benefit. These females have generally inherited the disease associated allele by their affected sib, but since their mother’s carrier status is uncertain their own risks remain in the middle range. The only option for such females, if deletion screening is not possible, is exclusion analysis on male fetuses to confirm the presence or absence of the disease associated allele, though the high number of false positives may be unacceptable to many women.

In the future the application of RFLP analysis may become more limited as effective counselling reduces the number of female carriers requiring analysis and sporadic cases contribute increasingly to the percentage of families seeking analysis. Thus, alternative methods of carrier detection will be required. In cases where the affected male shows an exon deletion then exon dosage assessment may be appropriate if methods can be accurately standardised. Junction fragments are also useful although these are only detected in a small number of cases. Perhaps the most widely applicable methods for the detection of deletion carriers will be pulsed field gel electrophoresis and cosmid hybridisation. The use of antidystrophin antibodies may be appropriate in non-deletion families where females show equivocal serum CK values.

We wish to thank Dr L M Kunkel for providing the pERT probes and Dr R G Worton for the XJ1.1 probe. This work was supported by a Research and Development grant from the Department of Health and Social Services (Northern Ireland).

Carrier estimations in Duchenne muscular dystrophy families in Northern Ireland using RFLP analysis.
E D Kelly, C A Graham, A J Hill and N C Nevin

doi: 10.1136/jmg.27.2.101

Updated information and services can be found at: [http://jmg.bmj.com/content/27/2/101](http://jmg.bmj.com/content/27/2/101)

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: [http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to: [http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to: [http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)